Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
We now rank 3rd in pharmaceutical production by volume and 14th by value
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Subscribe To Our Newsletter & Stay Updated
